Nanoform makes US TV debut in Advancements with Ted Danson

Viewers will learn how Nanoform's award-winning CESS nanoparticle engineering technology can potentially double the number of drug candidates progressing into clinic

Nanoform, an innovative nanoparticle medicine enabling company, will be featured in an upcoming Advancements episode broadcasting via CNBC on 12 December at 2.30pm (ET). Hosted by Ted Danson, the Advancements series is an information-based educational show focusing on cutting-edge developments in a variety of fields. Its aim is to enlighten the public on how technology and innovation continue to transform the world.

Viewers will learn how Nanoform's award-winning CESS nanoparticle engineering technology can potentially double the number of drug candidates progressing into clinic. The use of Nanoform’s unique process to open up new drug delivery routes and improve the lives of patients worldwide will also be explored.

The TV feature represents a valuable opportunity for Nanoform to increase awareness of its technology globally. Following its broadcast, the episode will be available for on-demand viewing on Amazon Prime Video. On 9 December at 12pm (ET) Nanoform will bring public attention to the episode with a 15-minute advertisement on the Thomson Reuters building in Times Square, New York City.

Prof. Edward Hæggström, Nanoform CEO, commented "Innovation has real impact when people know about it, and we are thrilled to partner with Advancements to show the power of our technology to the public. Our driving force is to provide hope for patients by helping novel drugs progress to the market, and this feature will bring that vision to TV screens across the USA."

Christian Jones, Nanoform CCO: "From a Finnish start-up to the increasingly globalized company we are today, Nanoform’s journey continues to reach new heights. By partnering with Advancements, we will now be able to explain to viewers how our physics-based approach can solve one of Pharma’s biggest challenges by improving the solubility and bioavailability of new drug candidates."

Featured Companies

Nanoform (more information, website)